Severe hypoxemic respiratory failure: part 2--nonventilatory strategies.
ARDS is characterized by hypoxemic respiratory failure, which can be refractory and life-threatening. Modifications to traditional mechanical ventilation and nontraditional modes of ventilation are discussed in Part 1 of this two-part series. In this second article, we examine nonventilatory strategies that can influence oxygenation, with particular emphasis on their role in rescue from severe hypoxemia. A literature search was conducted and a narrative review written to summarize the use of adjunctive, nonventilatory interventions intended to improve oxygenation in ARDS. Several adjunctive interventions have been demonstrated to rapidly ameliorate severe hypoxemia in many patients with severe ARDS and therefore may be suitable as rescue therapy for hypoxemia that is refractory to prior optimization of mechanical ventilation. These include neuromuscular blockade, inhaled vasoactive agents, prone positioning, and extracorporeal life support. Although these interventions have been linked to physiologic improvement, including relief from severe hypoxemia, and some are associated with outcome benefits, such as shorter duration of mechanical ventilation, demonstration of survival benefit has been rare in clinical trials. Furthermore, some of these nonventilatory interventions carry additional risks and/or high cost; thus, when used as rescue therapy for hypoxemia, it is important that they be demonstrated to yield clinically significant improvement in gas exchange, which should be periodically reassessed. Additionally, various management strategies can produce a more gradual improvement in oxygenation in ARDS, such as conservative fluid management, intravenous corticosteroids, and nutritional modification. Although improvement in oxygenation has been reported with such strategies, demonstration of additional beneficial outcomes, such as reduced duration of mechanical ventilation or ICU length of stay, or improved survival in randomized controlled trials, as well as consideration of potential adverse effects should guide decisions on their use. Various nonventilatory interventions can positively impact oxygenation as well as outcomes of ARDS. These interventions may be considered for use, particularly for cases of refractory severe hypoxemia, with proper appreciation of potential costs and adverse effects.
Division of Pulmonary and Critical Care Medicine, New York Methodist Hospital, 506 Sixth St, Brooklyn, NY 11215, USA. sur9016@nyp.org
Suhail
S
Raoof
Keith
K
Goulet
Adebayo
A
Esan
Dean R
DR
Hess
Curtis N
CN
Sessler
D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000465:Algorithms; D015199:Extracorporeal Membrane Oxygenation; D005440:Fluid Therapy / Q000379:methods; D006801:Humans; D000860:Hypoxia / Q000209:etiology / Q000628:therapy; D009466:Neuromuscular Blocking Agents / Q000627:therapeutic use; D009569:Nitric Oxide / Q000627:therapeutic use; D018529:Nutritional Support; D010656:Phenylephrine / Q000627:therapeutic use; D016684:Prone Position; D044062:Prostaglandins I / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic; D012121:Respiration, Artificial; D012128:Respiratory Distress Syndrome / Q000150:complications* / Q000628:therapy*; D012131:Respiratory Insufficiency / Q000209:etiology / Q000628:therapy; D014665:Vasodilator Agents / Q000627:therapeutic use
D000305:Adrenal Cortex Hormones; D009466:Neuromuscular Blocking Agents; D044062:Prostaglandins I; D014665:Vasodilator Agents; D010656:Phenylephrine; D009569:Nitric Oxide